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Objective: Based on the TAX 327 Phase III trial, docetaxel (DTX)-based chemotherapy is the standard
ﬁrst-line treatment for metastatic castration-resistant prostate cancer (mCRPC). However, some het-
erogeneity is observed in clinical practice. The present study aimed to evaluate the outcomes of a weekly
low-dose DTX regimen, which is clinical practice at our institution, and to compare it with the standard
triweekly DTX use in the TAX 327 trial.
Materials and methods: We reviewed the charts of all mCRPC patients treated with DTX 30 mg/m2
weekly on Days 1 and 8 of a 3-week cycle and prednisolone 5 mg twice daily between January 2006 and
February 2014 in our hospital.
Results: In the ﬁrst-line setting, 19 patients with mCRPC received weekly DTX chemotherapy. The me-
dian four cycles of treatment were given in our cohort. The median follow-up period from the start of
chemotherapy was 27.9 months (range 5.4e67.2months). The prostate-speciﬁc antigen (PSA) response
rate was 47.3%, and the median overall survival was 15.8 months (range 1.2e34.5 months). The main
toxicities were anemia (57%), fatigue (26%), and neuropathy (10%). Two patients had different Grade 3 to
4 adverse events (neutropenia and anemia). Our results revealed initial PSA <100 ng/mL, long duration
(>12 months) of response to primary hormone therapy, rechallenge, and a higher accumulation dose of
DTX were associated with good prognosis.
Conclusion: For Taiwanese mCRPC patients, weekly DTX 30 mg/m2 is an efﬁcient regimen for disease
control with relatively low Grade 3 or 4 hematological adverse effects. The proper treatment duration of
DTX therapy for mCRPC in Taiwanese patients is still uncertain, so further research is needed.
Copyright © 2015, Taiwan Urological Association. Published by Elsevier Taiwan LLC. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The incidence of prostate cancer has been rapidly increasing in
Taiwan: in 2011, prostate cancer became the ﬁfth most common
cancer in males, and in 2013, it resulted in 1207 deaths.1 Moreover,
about half of Taiwanese patients present with locally advanced or
metastatic disease upon diagnosis, which is quite different from
that in Western countries, where localized disease is found in mostRoad, Nei-Hu District, Taipei
om, doc20283@gmail.com
ociation. Published by Elsevier Tanew cases.2 The standard initial treatment for metastatic prostate
cancer is androgen deprivation therapy, which leads to an
improvement in bone pain, a regression of soft-tissue metastases,
and a reduction in serum levels of prostate-speciﬁc antigen (PSA).3
However, most patients eventually develop metastatic castration-
resistant prostate cancer (mCRPC). In 2004, the US Food and Drug
Administration approved docetaxel (DTX) for the treatment of
mCRPC. The triweekly regimen (75 mg/m2 every 3 weeks)
demonstrated a survival beneﬁt in the TAX 327 and Southwest
Oncology Group (SWOG) 9916 Phase III trials and is now the
standard ﬁrst-line therapy for symptomatic mCRPC patients.
However, hematologically adverse events seem to bemore frequent
in Asian patients than in the TAX 327 patients, especially among
elderly patients.4iwan LLC. This is an open access article under the CC BY-NC-ND license (http://
C.-L. Kao et al. / Urological Science 26 (2015) 267e270268In the TAX 327 study, 1006 patients with advanced prostate
cancer received 5 mg prednisone twice daily plus 12 mg/m2
mitoxantrone every 3 weeks, 75 mg/m2 DTX every 3 weeks, or
30 mg/m2 DTX once weekly for 5 of every 6 weeks. Median survival
in the two DTX arms was 18.9 months and 17.4 months, versus 16.5
months in the mitoxantrone group. The triweekly higher-dose DTX
regimen was associated with more neutropenia events than the
weekly low-dose regimen.
No clear consensus exists regarding the optimum duration and
dosage of DTX chemotherapy in Taiwanese patients to minimize
side effects with equal efﬁcacy. Moreover, standard triweekly DTX
therapy often causes hematologically adverse events and leads to
the discontinuation of chemotherapy in our clinical practice. To
reduce adverse events and their related mortality, we used a low-
dose regimen with DTX 30 mg/m2 on Days 1 and 8 of a 3-week
cycle and prednisolone 5 mg twice daily. This study aimed to
retrospectively assess the differences in efﬁcacy and adverse events
in this low-dose DTX protocol.2. Materials and methods
After approval was obtained from the institutional research
board, a retrospective analysis was performed of all mCRPC pa-
tients treated with DTX 30 mg/m2 on Days 1 and 8 of a 3-week
cycle and prednisolone 5 mg twice daily at a center between
2006 and 2013. Data from 19 consecutive patients were retro-
spectively analyzed. Eligible patients were diagnosed as having
metastatic adenocarcinoma of the prostate and castration resis-
tance. Castration-resistant prostate cancer (CRPC) was deﬁned as a
serial increase in serum PSA level on three consecutive examina-
tions, 2 weeks apart, resulting in two 50% increases over the nadir
with PSA >2.0 ng/mL or the enlargement of any lesion on radio-
graphic examination, even with a castration level of serum
testosterone. PSA was used as the primary criterion to assess
response and progression; radiography and bone scans were used
as additional data. PSA response was deﬁned as a decline of 50%
from the baseline value. PSA progression was deﬁned as a 50%
increase from the baseline in nonresponders or a 50% increase
from the nadir in responders. Progression-free survival and overall
survival (OS) were measured from the date of initiation of DTX to
the date of the ﬁrst event (progression or death) or the last follow
up. Toxicity was graded according to the Common Terminology
Criteria for Adverse Events (version 3.0, 2003). Duration of
response to primary hormone therapy was deﬁned as the time
from the date of initiation of hormone therapy against prostate
cancer to the date of CRPC diagnosis. All statistical analyses were
performed using SAS 9.2 (SAS Institute, Cary, NC, USA). Analyses
were performed using the Cox proportional hazards regression
model. A p value < 0.05 was considered signiﬁcant.Table 1
Patient characteristics.
Number
Age at chemotherapy (years)
Gleason score
Duration of responses to primary ADT (months)
PSA at chemotherapy (ng/mL)
Sites of metastases
Lymph node
bone
others
Cycles of DTX treatment
Observation period after initiation of DTX (months)
*DTX ¼ docetaxel; ADT ¼ androgen deprivation therapy.3. Results
This study enrolled a total of 19 Taiwanese patients between
January 2006 and February 2014. The characteristics of the patients
are listed in Table 1. The median age was 69 years (range 50e83
years). All patients had an ECOG performance status of 0e2. The
median total Gleason score was 9 (7e10). Two patients had un-
dergone radical prostatectomy, and four patients received deﬁni-
tive (n ¼ 2) or salvage (n ¼ 2) radiation therapy. Prior to DTX
treatment, all patients had received hormone therapy, including
castration and anti-androgen agents (bicalutamide and ﬂutamide).
The median serum pre-DTX-treatment PSA level was 102 ng/mL
(range 14.7e865 ng/mL). The patients had metastatic lesions in
bone (n ¼ 18; 94.7%), lymph nodes (n ¼ 10; 52.6%), or visceral
metastases (n ¼ 4; 21%). The median follow-up period from the
start of chemotherapy was 27.9 months (range 5.4e67.2 months).
The median number of cycles administered was 4 (range 1e8). The
PSA response rate was 47.3%, and the median duration of response
was 7.6 months. The median progression-free survival was 5.1
months [95% conﬁdence interval (CI) 3.9e6.3], and the median OS
was 15.8 months (95% CI 12.0e19.4). Three patients received
rechallengewith the same dose, and two of them had PSA response.
The responses to treatment are summarized in Table 2.
Three patients stopped chemotherapy before the planned four
cycles: two of them because of disease progression and one because
of treatment toxicity and infection. No patient required a dose
reduction before completing their course. One patient died of
infection during chemotherapy. The most common adverse effects
in our cohort were nail change (26%), fatigue (26%), and vomiting
(21%). Only Grade III neutropenia and Grade III anemia were
observed. The chemotherapy toxicities of our patients and the TAX
327 trial patients are summarized in Table 3.
To identify prognostic factors associated with OS, we performed
analyses with Cox proportional hazards regression models
(Table 4). Initial PSA <100 ng/mL, duration of response to primary
hormone therapy >12 months, and DTX rechallenge were associ-
ated with good prognosis, and a higher accumulation dose of DTX
also showed a trend of prolonged survival.4. Discussion
In 2004, the TAX 327 and SWOG 9916 studies showed DTX
chemotherapy had a signiﬁcant survival beneﬁt for men with
mCRPC.5,6 The TAX 327 study randomly assigned 1006 men with
mCRPC to receive DTX 75 mg/m2 every 3 weeks, DTX 30 mg/m2
weekly for 5 of 6 weeks, or mitoxantrone 12 mg/m2 every 3 weeks,
each with prednisone 5 mg twice daily. The study showed signiﬁ-
cantly longer survival for the q3w arm. The SWOG trial also showed
that treatment of CRPC with estramustine and DTX q3w results inMedian (range) or No. (%) of cases
19
69 (50e83)
9 (7e10)
10.6 (2e46)
102 (14.7e865)
10
18
4
4(1e8)
31.5
Table 2
Treatment responses.
Weekly DTX in our cohort Weekly DTX in TAX327 Tri-weekly DTX in TAX327
PSA response rate
Rate (%) 47.3 48 45
95% conﬁdence interval 24.3e70 42e54 40e51
Overall survival
Median (months) 15.8 17.4 18.9
95% conﬁdence interval 12.0e19.4 15.7e19.0 17.0e21.2
Decrease in pain
Rate (%) 31.5 31 35
95% conﬁdence interval 10e53
Duration of respone in responders
Median (months) 7.6 7.7 8.2
95% conﬁdence interval 5.5e7.9 7.1e8.6 6.3e11.5
Table 3
Adverse events.
Event Weekly DTX in our cohort No.(%)of cases Weekly DTX in TAX327 percent of cases Tri-weekly DTX in TAX327 percent of cases
Gr 3 or 4 Neutropenia 1 (5) 2 32
Febrile neutropenia 0 0 3
Gr 3 or 4 Thrombocytopenia 0 0 1
Gr 3 or 4 anemia 1 (5) 5 5
Fatigue 5 (26) 49 53
Gr 3 or 4 fatigue 0 5 5
Diarrhea 2 (10) 34 32
Anorexia 2 (10) 21 17
Vomiting 4 (21) 41 42
Peripheral neuropathy 2 (10) 12 19
Myalgia 1 (5) 14 14
Peripheral edema 3 (16) 12 19
Nail changes 5 (26) 37 30
Alopecia 4 (21) 50 65
C.-L. Kao et al. / Urological Science 26 (2015) 267e270 269longer median survival than treatment with mitoxantrone and
prednisone. Because of these two important trials, DTX q3w is now
the ﬁrst-line standard of treatment for patients with CRPC. How-
ever, hematological toxicity, especially neutropenia and neu-
tropenic sepsis, is always a concern with chemotherapy regimens
employing high-dose DTX, reaching even higher than 72%.7 Low-
dose DTX with weekly or biweekly schedules is more tolerable,
and many studies have demonstrated survival beneﬁts with lower
hematological toxicity.8e13
To date, the present study is the only one that analyzes the ef-
ﬁcacy and adverse events of weekly DTX chemotherapy in Taiwa-
nese CRPC patients. The patient characteristics, such as age and
baseline PSA, were similar to those in the TAX 327 trial, but our
cohort had more patients (8) with high Gleason scores (74% vs.
31%) and lowmedian accumulation dose (330 mg/m2 vs. 712.5 mg/
m2). Our regimen had comparable response rates, pain relief rates,
and duration of response with those of the TAX 307 trial. However,
the median OS of our patients (15.7 months) was inferior to that in
the q1w (17.4 months) and q3w (18.9 months) arms of the TAX 327Table 4
Analyses of the prognostic factors of overall survival in weekly DTX treatment.
Vairables
HR
Age<70 yrs vs >70 yrs 0.55
Initial PSA >100ng/ml vs <100ng/ml 4.41
Accumulation dose >600mg/m2 vs <600mg/m2 0.30
Time from ADT therapy to CRPC >12 mos vs <12mos 0.27
Visceral metastasis vs bony metastasis 1.40
PSA response vs no PSA response 0.49
Re-challenge vs no rechallenge 0.19trial. A high Gleason score and low accumulation dose are believed
to be adverse prognostic factors,14,15 so they may have caused the
difference in OS between the TAX 327 trial and our study. Three
patients in our study received DTX rechallenge with variable cycles
(5e8), and two of them had PSA response and relatively longer OS.
This data suggests that more cycles of the weekly low-dose DTX
regimen are probably needed to achieve better oncological
outcomes.
Compared with the triweekly regimen of the TAX 327 trial, our
weekly regimen caused few cases of adverse events, such as fatigue,
diarrhea, peripheral neuropathy, vomiting, and Grade 3 or 4 neu-
tropenia. Our weekly regimen seems to be a safe treatment for
fragile patients. Avoiding treatment complications is an important
consideration for CRPC patients who have undergone DTX
chemotherapy because two-thirds of prostate-cancer-related
deaths occur in men aged 75 years or older and many patients
have comorbid disorders.16
Moreover, treatment options following DTX chemotherapy for
patients with mCRPC are rapidly increasing, and new agents haveUnivariate Analysis
95% CI p
0.20 1.48 0.23
1.32 14.76 0.02
0.08 1.11 0.07
0.09 0.88 0.03
0.44 4.44 0.57
0.18 1.33 0.16
0.04 0.88 0.03
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include cabazitaxel,17 abiraterone,18 enzalutamide,19 and radium-
223.20 These advances have changed the standard of care, and
additional studies are needed to ﬁnd the best way of giving them
either in combination or as sequential single agents. For ﬁrst-line
treatment, patient safety and complication avoidance are
becoming more and more important.
To improve the strategy of weekly DTX chemotherapy, identi-
fying prognostic factors is a key step. We analyzed our patients'
data to explore the prognostic factors for survival outcomes in
Taiwanese patients. The result demonstrated that initial PSA
<100 ng/mL, duration of response to primary hormone therapy >12
months, and DTX rechallengewere associated with good prognosis,
and a higher accumulation dose of DTX also showed a trend of
prolonged survival. Several studies focused on prognostic factors in
Asian CRPC patients who had undergone a standard dose of DTX
chemotherapy, and concluded that alkaline phosphatase value,
visceral metastasis, PSA doubling time, baseline hemoglobin con-
centration, cycles of chemotherapy, and time to castration resis-
tance were independent prognostic factors.14,21 Some of these
markers were not available in our patients, so they were not used in
our study. Combining these prognostic factors may further reﬁne
the risk stratiﬁcation model and help in selecting the appropriate
time for the initiation and duration of DTX chemotherapy. Once
patients progress on androgen deprivation therapy, we suggest
DTX chemotherapy should be offered regardless of symptoms to
maximize DTX accumulation dose with low initial PSA levels. Our
regimen should be more tolerable in asymptomatic patients.
This study had several limitations. First, it was a single-center
study with a small number of patients. Second, it was a retro-
spective study, but some important data were unavailable in the
chart review. Finally, the observation period may not have been
long enough to determine the actual OS pattern. Despite these
limitations, however, the results suggest that DTX 30 mg/m2
weekly is an efﬁcient regimen with relatively few Grade 3 or 4
hematological adverse events. To achieve the best clinical beneﬁt
with few adverse events, future prospective studies should be
performed to determine the appropriate timing and cycles of this
weekly DTX regimen.
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